- St. Jude Medical (NYSE:STJ) Q1 net profit $249M vs $223M.
- Constant currency sales +4%.
- Sales breakdown: Cardiac Rhythm Management (CRM) +1% to $687M, with U.S. ICD sales +5%; Atrial Fibrillation (AF) +8% to $251M; Cardiovascular -1% to $326M; Neuromodulation flat at $99M.
- Outlook: Q2 adjusted EPS of $0.99-1.01 vs consensus of $1 and revenues of $1.38-1.46B vs $1.44B; FY EPS of $3.95-4.00 vs $4.30 and revenue of $5.61-5.76B vs $5.96B.
- St. Jude expects four new CRM product approvals in the U.S. to accelerate sales in H2. (PR)
- Previous